What is claimed is:

1. Use of esomeprazole or 5-O-desmethyl-omeprazole (RS-D7) or a therapeutically acceptable salt, solvate or stereoisomer thereof in the manufacture of a medicament for treating and/or preventing a disease associated with D-amino acid oxidase (DAAO) inhibition in a human.

2. The use of Claim 1, wherein the effective amount of the compound or a therapeutically acceptable salt, solvate or stereoisomer thereof is 2 mg/kg body weight to 5 g/kg body weight.

3. The use of Claim 1 or 2, wherein the disease associated with DAAO inhibition is selected from the group consisting of schizophrenia, schizoaffective disorder, mild cognitive impairment (MCI), depression, Tourette Syndrome, ataxia, Post-traumatic stress disorder (PTSD), Obsessive-compulsive disorder (OCD), pain, convulsion, dementia, loss of memory and/or cognition associated with neurodegenerative diseases and loss of neuronal function characteristic of neurodegenerative diseases.

4. The use of Claim 3, wherein the schizophrenia and schizoaffective disorder include negative, cognitive, depressive, positive and general psychopathology symptom domains.

5. The use of Claim 3, wherein the disease associated with DAAO inhibition is mild cognitive impairment (MCI), Alzheimer’s disease, Parkinson’s disease or schizophrenia.

6. The use of Claim 3, wherein the disease associated with DAAO inhibition is pain, ataxia or convulsion.

7. The use of any one of Claims 1-6, wherein the medicament is a pharmaceutical composition comprising pharmaceutical acceptable carriers and/or excipients.

8. The use of any one of Claims 1-7, wherein the medicament for oral, parenteral, intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous, intramedullary, intraarticular, infusion, intrathecal, epidural, intraduodenal, transdermal, nasal aerosol, inhalation, rectal or vaginal administration.